Benzinga's Top #PreMarket Losers
March 31, 2014 at 08:18 AM EDT
Prana Biotechnology (NASDAQ: PRAN) dipped 66.94% to $3.26 in the pre-market session on failed Phase 2 Alzheimer's trial ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.